Journal of Oncology

Cancer Stem Cells


Publishing date
01 Feb 2011
Status
Published
Submission deadline
01 Aug 2010

Lead Editor

1Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA

2Institute of Pharmacology/Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

3Département de Radiothérapie, Institut Gustave Roussy, Rue Camille Desmoulins, Villejuif, France

4Department of Drug Development, Nevada Cancer Institute, Las Vegas, NV, USA


Cancer Stem Cells

Description

With the realization of the powerful therapeutic effect of synergistic multimodality approaches to cancer treatment, scientists have made significant strides in the treatment of cancer. Coupling this knowledge with new discoveries in neoplastic stem cell dependency, we have yet another mechanism of combinatorial synergy that may soon be an exploitable weapon in physicians' therapeutic arsenal. Considering the profound curative possibilities that arise from these advancements, it is imperative that we explore this novel approach further. The basic scientific foundations for targeted neoplastic stem cell therapy have now been laid, and there are already several pharmacologic agents available that are capable of specifically modulating signaling within cancer stem cells (CSC), with more in development. Still, more research is needed in the basic physiologic signaling mechanisms of cancer stem cells, and better methods for the disruption of CSC signaling must be developed if we are to fully integrate the CSC hypothesis into our treatment paradigms. Notably, CSCs may not necessarily need to be destroyed to stop cancer if they can be forced to advance down their lineage en masse as they do in the treatment of acute promyelocytic leukemia. In conclusion, it is paramount that future studies focus on the development of additional modalities designed to supplement the in vivo elimination of cancer stem cells.

We invite authors to present original research articles as well as review articles that will stimulate the continuing efforts in defining the role of targeting CSCs in oncology. We are particularly interested in manuscripts that report the preclinical and clinical applications of investigational anti-CSC therapy, with emphasis on novel concepts, efficacy, toxicity, response assessment, multimodality treatment, prognostic factors, and predictive markers, but reports on multitargeted therapy that include targeting CSCs that are also welcomed. Reviews that summarize the results of latest preclinical investigations and clinical trials and their implications on treatment practice in various malignancies are welcomed.

Potential topics include but are not limited to:

  • Preclinical investigations on concepts of integrating novel pipeline drugs against CSCs in cancer therapy
  • Clinical efficacy and toxicity of anti-CSC therapy in common cancers
  • Combination of anti-CSC therapy with chemotherapy and/or radiotherapy
  • Clinical or biological markers as outcome predictor

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jo/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2011
  • - Article ID 269437
  • - Editorial

Cancer Stem Cells

Bo Lu | Shih-Hwa Chiou | ... | Aurelio Lorico
  • Special Issue
  • - Volume 2011
  • - Article ID 798592
  • - Research Article

Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities

M. Affer | S. Dao | ... | B. D. Clarkson
  • Special Issue
  • - Volume 2011
  • - Article ID 135039
  • - Review Article

Phenotypic Heterogeneity of Breast Cancer Stem Cells

Aurelio Lorico | Germana Rappa
  • Special Issue
  • - Volume 2011
  • - Article ID 946936
  • - Research Article

Survivin Selectively Modulates Genes Deregulated in Human Leukemia Stem Cells

Seiji Fukuda | Mariko Abe | ... | Louis M. Pelus
  • Special Issue
  • - Volume 2011
  • - Article ID 591427
  • - Review Article

Cooperation of Cancer Stem Cell Properties and Epithelial-Mesenchymal Transition in the Establishment of Breast Cancer Metastasis

Tetsu Hayashida | Hiromitsu Jinno | ... | Masaki Kitajima
  • Special Issue
  • - Volume 2011
  • - Article ID 549181
  • - Review Article

Lung Cancer Stem Cell: New Insights on Experimental Models and Preclinical Data

Caroline Rivera | Sofia Rivera | ... | Eric Deutsch
  • Special Issue
  • - Volume 2011
  • - Article ID 852970
  • - Review Article

Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors

Sanna-Maria Hede | Inga Nazarenko | ... | Mikael S. Lindström
  • Special Issue
  • - Volume 2011
  • - Article ID 352616
  • - Review Article

Loss of Function of E-Cadherin in Embryonic Stem Cells and the Relevance to Models of Tumorigenesis

Lisa Mohamet | Kate Hawkins | Christopher M. Ward
  • Special Issue
  • - Volume 2011
  • - Article ID 465343
  • - Review Article

Cancer Stem Cells: Repair Gone Awry?

Fatima Rangwala | Alessia Omenetti | Anna Mae Diehl
  • Special Issue
  • - Volume 2011
  • - Article ID 762780
  • - Review Article

Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma

Marcus M. Monroe | Eric C. Anderson | ... | Melissa H. Wong
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
CiteScore1.400
Impact Factor2.206
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.